Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cronos Group Inc (CRON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cronos Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Cronos Group Inc trades at $2.77 (market cap $1.03B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4.4× Cronos Group Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CRON | |
|---|---|---|
Market Cap | $4.49B | $1.03B |
Sector | Health | Health |
52-Week High | $28.06 | $3.27 |
52-Week Low | $20.06 | $1.95 |
Enterprise Value | $3.69B | $205.93M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
